Switzerland Daily Monitor
SEE OTHER BRANDS

Your daily news update on Switzerland

Switzerland Daily Monitor: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Switzerland Daily Monitor.

Press releases published on May 6, 2025

DemaTrading Powers Next-Gen Crypto ETP Rebalancing with Issuance Swiss

DemaTrading Powers Next-Gen Crypto ETP Rebalancing with Issuance Swiss

Issuance Swiss integrates DemaTrading to automate crypto ETP rebalancing, boosting scalability, compliance, and speed for fund managers. AMSTERDAM, NOORD-HOLLAND, NETHERLANDS, May 6, 2025 /⁨EINPresswire.com⁩/ -- DemaTrading, a rising force in digital …

Balfour Capital Welcomes Mohammad Saif as Investment Advisor

Balfour Capital Welcomes Mohammad Saif as Investment Advisor

Hedge Funds, Investments, Trading YVERDON-LES-BAINS , SWITZERLAND, May 6, 2025 /⁨EINPresswire.com⁩/ -- Balfour Capital Group Strengthens Global Investment Team with Appointment of Accomplished Analyst Specializing in Multi-Asset Strategies Balfour …

Balfour Capital Welcomes Tadas Sidlauskas  as Investment Advisor

Balfour Capital Welcomes Tadas Sidlauskas as Investment Advisor

Hedge Funds, Investments, Trading YVERDON-LES-BAINS, SWITZERLAND, May 6, 2025 /⁨EINPresswire.com⁩/ -- Balfour Capital Group Welcomes Tadas Sidlauskas, Enhancing Quantitative Expertise and Global Investment Strategy Balfour Capital Group (BCG), a …

Balfour Capital Welcomes Leandro Vlach as Investment Advisor

Balfour Capital Welcomes Leandro Vlach as Investment Advisor

Hedge Funds, Investments, Trading YVERDON-LES-BAINS, SWITZERLAND, May 6, 2025 /⁨EINPresswire.com⁩/ -- Balfour Capital Group Expands Global Expertise with Appointment of Leandro Vlach, Financial Modeling Specialist Balfour Capital Group (BCG), a leading …

ViewsML Expands to Asia Pacific, In-Licensing Technology from A*STAR

ViewsML Expands to Asia Pacific, In-Licensing Technology from A*STAR

ViewsML expands to Singapore with A*STAR tech licensing agreement to enhance AI-powered virtual biomarker platform VANCOUVER, BRITISH COLUMBIA, CANADA, May 6, 2025 /⁨EINPresswire.com⁩/ -- ViewsML, an innovator in AI-driven spatial biology and virtual …

Bpifrance, Influence Society et L’ADN réunissent des leaders du tourisme autour de l’IA à Paris

Bpifrance, Influence Society et L’ADN réunissent des leaders du tourisme autour de l’IA à Paris

Un événement stratégique sur l’IA et ses usages concrets dans le secteur touristique, organisé à l’occasion de l’ouverture de l’hôtel La Fondation PARIS, FRANCE, May 6, 2025 /⁨EINPresswire.com⁩/ -- À l’occasion de l’ouverture de l’hôtel La Fondation, …

CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3

CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3

-Initial CTX310™ Phase 1 clinical data demonstrates dose-dependent decreases in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 81% in LDL, with a well-tolerated safety profile; presentation …

International Petroleum Corporation Announces First Quarter 2025 Financial and Operational Results

International Petroleum Corporation Announces First Quarter 2025 Financial and Operational Results

TORONTO, May 06, 2025 (GLOBE NEWSWIRE) -- William Lundin, IPC's President and Chief Executive Officer, comments: “We are pleased to announce another strong quarter of operational and financial performance for Q1 2025. IPC achieved an average net daily …

Novaremed Announces Completion of Enrollment in NIH-sponsored Phase 2b Study with Non-opioid NRD.E1 for the Treatment of Chronic Pain Associated with Diabetic Peripheral Neuropathy

Novaremed Announces Completion of Enrollment in NIH-sponsored Phase 2b Study with Non-opioid NRD.E1 for the Treatment of Chronic Pain Associated with Diabetic Peripheral Neuropathy

Last patient first visit (LPFV) marks completion of enrollment of 127 adult and elderly patients in the randomized, placebo-controlled trial -- topline data is expected in Q4 2025 This study builds on Phase 2a proof-of-concept results, which showed a …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service